Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

By Gail D Lewis Phillips, Guangmin Li, D. Dugger, Lisa M. Crocker, Kathryn L. Parsons, Elaine Mai, W. Blättler, J. Lambert, R. Chari, R. Lutz and 7 more. Cancer Research, 2008

1,596 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/44b7dae3d92bc89ec03ef8c62106550bf109d5f0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Antibody Drug Conjugates for Cancer Therapy (2016, background): “In the case of Kadcyla, preclinical efficacywas comparable to that observedwith the anti-HER2 ADC containing maytansinoids coupled through reducible linkers (Lewis Phillips et al., 2008).”
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (2012, background): “Indeed, the in vivo stability and efficacy of antibody conjugates can be improved by optimizing the linke”
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 (2016, background): “Among theHER2-targeting drugs, T-DM1 is the only antibody– drug conjugate (ADC) in the market which is composed of trastuzumab and a tubulin polymerization inhibitor, DM1 (11).”
Microtubule-binding agents: a dynamic field of cancer therapeutics (2010, background): “Maytansine conjugates are being studied in various indications, in particular in haematological diseases and in breast cance”
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (2009, neutral): “Nevertheless, trastuzumab treatment does result in G1-S cell cycle growth arrest that does not lead to apoptosis (Lewis et al., 1996).”
Site-specific antibody drug conjugates for cancer therapy (2013, background): “Ado-trastuzumab emtansine, developed by Genentech with ImmunoGen’s ADC linker-drug technology, targets human epidermal growth factor receptor 2 (Her2)-positive breast cancer and combines an anti-Her2 antibody (trastuzumab) with the cytotoxic agent maytansine (DM1) via a stable linker.(18) Knowledge ”
Antibody Structure and Function: The Basis for Engineering Therapeutics (2019, background): “compared trastuzumab-DM1 conjugates containing a panel of reducible disulfide linkers and a non-reducible linker [377].”
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. (2011, background): “Additionally, T-DM1 seems to retain the antitumor properties of trastuzumab, including flagging HER2-positive tumor cells for destruction by antibody-dependent cellular cytotoxicity and inhibiting HER2 signaling (data on file, Genentech, South San Francisco, CA).(12,13) A phase I dose-escalation stu”
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009, background): “Trastuzumab–DM1 (T–DM1; Genentech) consists of the trastuzumab antibody conjugated to the potent anti-microtubule agent DM1 (a maytansine derivative”
Antibody therapy of cancer (2012, background): “These antibody conjugates have provided the first proof-in-principle for antibodies selectively delivering drug payloads to cancer cells, and a similar approach in patients with advanced ERBB2-positive breast cancer with the antibody–drug conjugate trastuzumab–emtansine (also known as T-DM1”